Table 2.
Prevalence of chromosome 17 aneusomy in invasive ERBB2 amplified* and non-amplified breast cancer estimated by FISH analysis
| Number of specimens | Disomy | Monosomy | Polysomy | Association with ERBB2 expression in ERBB2 non-amplified tumours | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||||||||
| Total | Amp* | Non-amp | Cutoff | Total N (%) | Amp N (%)* | Non-amp N (%) | Cutoff | Total N (%) | Amp N (%) | Non-amp N (%) | Cutoff | Total N (%) | Amp N (%) | Non-amp N (%) | ||
| Mezzelani et al (1998)41 | 58 | 24 | 28 | 2† | 20 (35) | 15 (63) | 5 (18) | 1† | 2 (3.4) | 1 (4.1) | 1 (3.6) | >2† | 5(8.6) | 4 (17) | 1 (3.6) | NR |
| Farabegoli et al (1999)42 | 79 | 19 | 60 | 2‡ | NR | NR | 15 (25) | 1‡ | NR | NR | 12 (20) | ≥3‡ | NR | NR | 33 (55) | NA |
| Jimenez et al (2000)43 | 34 | 10§ | 15§ | >80 | 14 (41) | 4 (40) | 9 (60) | >80∥ | 3 (8.8) | 1 (10) | 1 (6.7) | >80** | 5 (15) | 1 (10) | 1 (6.7) | NA |
| Bose et al (2001)44 | 74 | 8 | 66 | 2‡ | 46 (62) | 1 (13) | 45 (68) | 0–1‡ | 3 (4.1) | 0 (0) | 3(4.5) | 3–4‡ | 25 (34) | 7 (88) | 18 (27) | 3+ |
| Tubbs et al (2001)45 | 145 | 29 | 116 | NR | 92 (63)†† | 12 (41) | 80 (69) | NR | NR | NR | NR | NR | 53 (37) | 17 (59) | 36 (31) | NR |
| Varshney et al (2004)46 | 687 | 78 | 609 | NR | NR | NR | NR | NR | NR | NR | NR | ≥3‡ | 71 (10) | 30 (39) | 41 (6.7) | 3+ |
| Salido et al (2005)47 | 175 | 80†† | 95 | NR | 153 (87)†† | 72 (90) | 81 (85) | NR | 3 (1.7) | NR | NR | ≥3‡ | 22 (13) | 14 (18) | 8 (15) | 2–3+ |
| Downs-Kelly et al (2005)48 | 727 | 134 | 593 | NR | NR | NR | NR | NR | NR | NR | NR | >2.1‡ | 257 (35) | 54 (40) | 203 (34) | NA |
| Beser et al (2007)19 | 50 | 11 | 39 | 1.35–1.85‡ | 35 (70) | 9 (82) | 26 (67) | <1.35‡ | 6 (12) | 0 (0) | 6 (15) | >1.86‡ | 9 (18) | 2 (18) | 7 (18) | NR |
| Torrisi et al (2007)49 | 457 | 54 | 403 | NR | NR | NR | NR | NR | NR | NR | NR | ≥3‡ | 77 (17) | 9 (17) | 68 (17) | NR |
| Merola et al (2006)38 | 343 | 101 | 242 | 2‡ | 102 (30) | NR | NR | 1‡ | 83 (24) | 49 (49) | 34 (14) | >3‡ | 158 (46) | 24 (24) | NR | 2+ |
| Reinholz et al (2007)28 | 1888 | 1488 | 156 | Loss ≤60∥ | 625 (33) | 544 (37) | 81 (52) | >60∥ | 89 (4.7) | 79 (5.3) | 5 (3.2) | >30** | 935 (50) | 865 (58) | 70 (36) | NR |
| Gain ≤30** | ||||||||||||||||
| Vanden Bempt et al (2008)50 | 226 | 97§§ | 126 | NR | NR | NR | NR | NR | NR | NR | NR | >3‡ | 104 (46) | 42 (43) | 62 (49) | NA |
Amp=ERBB2 amplification. Non-amp=ERBB2 non-amplification. N=number of specimens. NR=not explicitly reported in reference. NA=ERBB2 expression was not associated with polysomy 17.
ERBB2 amplification defined as ERBB2/CEP17 ratio ≥2.0 unless otherwise indicated.
Disomy defined as 2 ERBB2 gene signals related to 2 chromosome 17 signals was found in all cells; monosomy defined as ERBB2 signals <chromosome 17 signals; polysomy defined as equal numbers of both signals and ratio >2.
Average number of chromosome 17 signals per nucleus.
ERBB2 amplification defined as: >80% with >5 ERBB2 signals per nucleus; ERBB2 non-amplification: >80% with ≤2 signals per nucleus. Percent of nuclei with 2 chromosome 17 signals per cell.
Percent of nuclei with loss of centromeric region or entire chromosome (typically with 0 or 1 chromosome 17 signal per cell).
Percent of nuclei with gain of centromeric region or entire chromosome (typically >2 or ≥3 chromosome 17 signals per cell).
Inferred from literature to be disomic.
‡‡ ERBB2 amplification defined by mode ERBB2 signal or mode chromosome 17 signal ≥2.
ERBB2 amplification defined as ERBB2/CEP17 ratio >2.2.